不同类型PTX治疗复发性卵巢癌的临床效果分析

Analysis of Clinical Effect of Different Types of PTX for the Treatment of Recurrent Ovarian Cancer

目的探讨白蛋白结合型紫杉醇(PTX)与PTX脂质体分别联合奈达铂化疗治疗复发性卵巢癌的临床效果及不良反应。方法回顾性分析本院妇科近年来化疗的97例晚期复发性卵巢癌患者临床资料。其中51例患者采用白蛋白结合PTX加奈达铂治疗(白蛋白组)、46例患者采用PTX脂质体加奈达铂治疗(脂质体组),对比两组的临床效果、毒副反应及预后差异。结果白蛋白组患者的缓解率52.94%显著高于脂质体组32.61%(P<0.05);白蛋白组的总有效率84.31%高于脂质体组73.91%,但差异无统计学意义(P>0.05);两组的各种严重毒副反应发生率差异均无统计学意义;白蛋白组与脂质体组患者治疗后第1年、2年生存率(78.43%、47.06%vs 67.39%、30.43%)间差异无统计学意义(P>0.05);但3年生存率白蛋白组显著高于脂质体组(29.41%vs 13.04%)。结论白蛋白结合PTX加用奈达铂治疗复发性卵巢癌患者的效果优于PTX脂质体加用奈达铂,且不会增加毒副反应。

Objective To study the clinical effects and side effects of albumin combined with paclitaxel （PTX） and PTX liposome combined with nedaplatin chemotherapy for the treatment of recurrent ovarian cancer. Methods 97 patients with advanced recurrent ovarian cancertreated by oncology chemotherapy were retrospectively analyzed, 51 patients were treated with albumin binding PTX ＋ nedaplatin therapy （albumin group）, 46 patients were treated with PTX liposome ＋ Nida platinum therapy （liposome group）, the clinical effect, toxicity and prognostic differences of the two groups were compared. Results Remission rate of albumin group （52. 94%）was significantly higher than the liposome group （ 32. 61% ） （ P 〈 0.05 ）, and the efficiency is 73.91% and 84.31%, repectively （ P 〉 0.05 ）. Serious adverse reaction rates showed no significant difference in the two groups （P〉0.05） ;Survival rates of patients of 1 and 2-year（78.43%, 47.06 vs 67.39%% 30.43% ）had no significant difference （P〉0.05）in the albumin group and liposome group.But, the 3-year sur- vival of albumin group is higher than that of the liposome group （29.41% vs 13.04%） （P〈0.05）. Conclusion Treat- merit of recurrent ovarian cancer patients with albumin together PTX and nedaplatin is better than that of PTX liposomes and Nedaplatin but without increasing toxicity,